BMO Capital Markets initiated coverage on AbbVie (NYSE: ABBV ) with an Outperform rating and a $39 price target. BMO Capital Markets commented, "We would be opportunistic buyers of ABBV in the low- to mid-$30s range. We believe the dividend yield (4.6%-5.3%) should support the stock at these levels.